Scopus BioPharma(OTC) SCPS

Scopus BioPharma Inc. is a biopharmaceutical company focused on developing innovative treatments for serious diseases, particularly in the field of immuno-oncology. The company is advancing its clinical programs through strategic collaborations with leading organizations, aiming to address various forms of cancer.

Products and Services

• Duet Platform featuring CpG signal transducer and STAT3 inhibitors
• MRI-1867, an orally administered dual-action small molecule
• Immuno-oncology gene therapies targeting multiple cancer types

Growth Outlook

• Strategic collaborations with City of Hope and NIH enhance research capabilities
• Focus on immuno-oncology positions the company in a growing market
• Potential for significant advancements in cancer treatment through innovative therapies

Financial Highlights

• Q2 2023 net income of -$2.6 million, reflecting ongoing R&D investments
• Cash and cash equivalents of $362,097 as of June 30, 2023
• Trailing twelve months (TTM) operating cash flow of -$3.9 million

Scopus BioPharma Inc. operates in a highly competitive biotechnology sector, focusing on groundbreaking therapies that address critical health challenges. The company's commitment to research and development is evident in its significant investments, with Q2 2023 research and development expenses totaling approximately $1.99 million. Despite reporting no revenue, the strategic partnerships and innovative product pipeline suggest a promising trajectory for future growth. The company’s financial position, with cash reserves of $362,097, indicates a need for continued funding to support its ambitious development goals. Investors may find interest in the potential of Scopus BioPharma to make impactful contributions to cancer treatment, particularly as the market for immuno-oncology therapies expands.